UGT1A1 and cancer: Minami et al. reported the pharmacokinetics of irinotecan in patients with or without UGT1A1*6 or *28 in 177 Japanese cancer patients, in which the area under the concentration curve ratio of SN-38G to SN-38 was lower in patients with one and two haplotypes harboring *6 or *28 than in those without *6 or *28, and lowest in patients with two haplotypes harboring *6 or *28 [42].